**INVESTIGATION**

**Translation, cross-cultural adaptation and validation of the vitiligo-specific health-related quality of life instrument (VitiQoL) into Brazilian Portuguese**

Juliana Catucci Boza1  
Amanda Fabbrin1  
Natalia Giongo1  
Roopal V Kundu2  
Roberta Horn1  
Tania Ferreira Cestari1

DOI: http://dx.doi.org/10.1590/abd1806-4841.20153684

**Abstract: Background:** Vitiligo, although asymptomatic, highly compromises patients’ quality of life (QoL). Therefore, an adequate evaluation of QoL is essential.

**Objectives:** Translation, cultural adaptation and validation of VitiQoL (Vitiligo-specific health-related quality of life instrument) into Brazilian Portuguese.

**Methods:** The study was conducted in two stages; the first stage was the translation and cultural/linguistic adaptation of the instrument; the second stage was the instrument’s validation.

**Results:** The translated VitiQoL showed high internal consistency (Cronbach alpha = 0.944) and high test-retest reliability and intraclass correlation coefficient=0.95 (CI 95% 0.86 - 0.98), p<0.001. There was no statistically significant difference between the means of the first completion of the VitiQoL questionnaire and the retest, p = 0.661. There was a significant correlation between VitiQoL and DLQI (r = 0.776, p <0.001) and also between VitiQoL-PB and subjects’ assessment of the severity of their disease (r = 0.702, p <0.001).

**Conclusions:** The impact of vitiligo on the QoL of Brazilian patients can be assessed by a specific questionnaire.

**Keywords:** Indicators of quality of life; Quality of life; Sickness impact profile; Vitiligo

---

**INTRODUCTION**

Vitiligo is an acquired pigmented disorder, characterized by achromatic spots due to a loss of melanocytes. Its prevalence ranges between 0.5% and 1% worldwide. Gujarat, India, is considered to be the place with the highest prevalence of vitiligo: approximately 8.8%.¹ The average age of onset is 22 years in the United States and India, 24 years in Brazil and 25 years in England, and half of the patients develop the disease before 20 years of age.¹²³ Adults and children of both genders are equally affected, but some studies indicate a slight preponderance of cases among females, possibly because women seek medical care more often than men due to the secondary psychosocial consequences.¹²³ There is no predilection for skin type or race.¹

There are genetic factors involved in its etiopathogenesis, and the relative risk of vitiligo in first-degree relatives is estimated as seven to 10 times greater than in the general population.¹² Other aspects involved include autoimmunity, intrinsic defects of melanocytes and T-cells, and oxidative stress.⁸⁻¹¹ Many dermatological diseases are characterized by compromising patients’ physical and relational well-being. For this reason, the assessment of quality of life (QoL) is of fundamental importance.¹²⁻¹⁰ Vitiligo, although asymptomatic, highly compromises QoL. It affects patients’ lives in many ways, being sometimes psychologically devastating. The condition compromises self-esteem, body image and social life. Individuals with vitiligo suffer social discrimination and stigmatization, which result in significant chang-
es in their lifestyles: from the choice of clothing, use of sunscreen and cosmetic camouflage of the lesions to the avoidance of social events or outdoor activities.14,17

Recently, a specific questionnaire for vitiligo has been developed and validated in the English language: the Vitiligo-specific health-related quality of life instrument (VitiQoL).17 To this date, there were no instruments in Brazilian Portuguese to assess the QoL in vitiligo.

The VitiQoL is a questionnaire of 15 items, with item scores from 0 (never) to 6 (all the time). It yields a total score from 0 to 90. Moreover, it presents a personal assessment of the severity of vitiligo, using a scale ranging from 0 (no skin involvement) to 6 (most severe cases), which corresponds to the 16th question of the VitiQoL questionnaire. The questionnaire shows to be a promising clinical and epidemiological study instrument, and a powerful marker of outcome.15,17

The aim of this study was to perform the translation, cross-cultural adaptation and validation of the VitiQoL into Brazilian Portuguese (VitiQoL-PB).

METHODS

The author of the VitiQoL questionnaire authorized its translation, cross-cultural adaptation and validation. The study was conducted in two stages: the first stage was the translation and cultural/linguistic adaptation of the instrument; the second stage was the instrument’s validation. This is an observational study. Subjects were divided into two groups: cross-sectional and follow-up (retest). Subjects were selected from a Dermatological Outpatient Clinic from Hospital de Clínicas de Porto Alegre. In this study, we used convenience sampling of consecutive cases. Inclusion criteria were: older than 18 years of age; able to read and understand Brazilian Portuguese; diagnosis of vitiligo confirmed by a dermatologist. Exclusion criteria were: presence of chronic, non-dermatological disease or other concomitant dermatological disease.

In the first stage (translation and cross-cultural adaptation), two independent translators performed the literal translation of the VitiQoL instrument from English into Portuguese. This version was later reviewed by a bilingual group, composed of health professionals. Next, 10 subjects with vitiligo were asked to answer the questionnaire and make suggestions for its clarity and understanding. After repeat review by the same bilingual group, this new version of the questionnaire was translated into English and sent to the author of the original questionnaire for approval. This stage took place from January to June 2013.

Based on the original study and the WHO recommendations for the development of quality of life questionnaires, a specific questionnaire on demographic data, the VitiQoL questionnaire and a generic instrument for dermatological diseases previously validated for Portuguese, the DLQI (Dermatology Life Quality Index), were administered to 74 subjects. In addition, subjects made a personal assessment of their severity of vitiligo, using a scale ranging from 0 (no skin involvement) to 6 (most severe cases), which corresponded to the 16th question of the VitiQoL-PB questionnaire.

For test-retest reliability, the sample was calculated based on the studies reliability graph, using a reliability coefficient (Cronbach’s coefficient) of 0.80 and a confidence interval of 0.05. Statistical analysis was performed using SPSS (SPSS Inc. Chicago, IL, version 18.0 for Windows). The reliability of the instrument was demonstrated through the analysis of internal consistency using Cronbach’s coefficient of reliability. Test-retest reliability was assessed by intraclass correlation coefficient (ICC) and Student t test for paired samples. The PB-VitiQoL and DLQI were compared using the Pearson correlation coefficient. General data were analyzed using descriptive statistics (mean and standard deviation for quantitative variables with symmetric distribution; median and interquartile range for variables with asymmetric distribution; and frequencies and percentages for categorical variables). The study project was approved by the Research Ethics Committee and all subjects signed an informed consent.

RESULTS

The questionnaire was completed by 74 subjects. For analysis of reproducibility (test-retest reliability), two to four weeks after the first interview, a subgroup of subjects, corresponding to 20% of the sample, completed the VitiQoL-PB questionnaire again. Subjects’ demographic and clinical characteristics are described in table 1. The translated VitiQoL showed high internal consistency (Cronbach alpha = 0.944) and high test-retest reliability, with an intraclass correlation coefficient of 0.95 (CI 95% 0.86 - 0.98), p<0.001. There was no statistically significant difference between the means of the first completion of the VitiQoL questionnaire and the retest, p = 0.661 (Graph 1]). The 95% interval of agreement between the test and retest was -25.46 to 22.71.

The single item that most contributed to the total score of VitiQoL-PB was related to the frustration about the skin condition (question 2). Other items that significantly contributed to the final scores were: feeling bothered by the appearance of the skin (question 7), worry about what other people think (question 5), fear of criticism (question 6), embarrassment or inhibition because of the skin (question 7), social or leisure activities (question 9), emotional well-being (question 10).

In general, we found that all items contributed to the final score (Table 2).
The average VitiQoL-PB score was 40.04±27.32, while the median DLQI was 3 (interquartile range P25 = 1 and P75 = 7). The average patient assessment score for severity of illness was 3.64 ± 1.87 (Figure 1).

There was a significant correlation between VitiQoL and DLQI (r = 0.776, p <0.001) and also between VitiQoL-PB and subjects’ assessment of the severity of their disease (r = 0.702, p <0.001). We also found a good correlation between the total DLQI and subjects’ assessment of the severity of their disease (r = 0.673, p <0.001) (Graph 2).

| Table 1: Clinical and demographic data |
|---------------------------------------|
| **Mean (standard deviation)**          |
| **Age**                                |
| 44.70 (17.10)                          |
| **Age of onset**                       |
| 31 (median)                            |
| **Duration of the disease**            |
| 11 (median)                            |
| **Gender**                             |
| Male                                  |
| 24 (32.4)                             |
| Female                                |
| 50 (67.6)                             |
| **Skin type**                          |
| II                                     |
| 12 (16.2)                             |
| III                                    |
| 31 (41.9)                             |
| IV                                     |
| 26 (35.1)                             |
| V                                      |
| 5 (6.8)                               |
| **Educational level**                  |
| Incomplete primary education           |
| 21 (28.4)                             |
| Complete primary education             |
| 3 (4.3)                               |
| Incomplete secondary education         |
| 13 (17.6)                             |
| Complete secondary education           |
| 12 (16.2)                             |
| Incomplete higher education            |
| 12 (16.2)                             |
| Complete higher education              |
| 13 (17.6)                             |
| **Marital status**                     |
| Married                                |
| 27 (36.4)                             |
| Divorced/ Separated                    |
| 12 (16.2)                             |
| Widowed                                |
| 6 (8.3)                               |
| Single                                 |
| 29 (39.1)                             |
| **Income**                             |
| up to 500.00                           |
| 3 (4.1)                               |
| 500.00-1,000.00                        |
| 20 (27)                               |
| 1,000.00-3,000.00                      |
| 33 (44.6)                             |
| >3,000.00                              |
| 16 (21.6)                             |
| Was unable to report                   |
| 2 (2.7)                               |

| Graph 1: Clinical and demographic data Bland and Altman’s graph showing agreement between test and retest scores. The solid line shows the difference between the means of the test and the retest; the dotted line shows the 95% limits of agreement (mean difference ± 1.96SD) |

| Table 2: Correlation between items and between the items with the final score |
|--------------------------|----------------|----------------|
| Item                     | Correlation between items | Correlation between the items and the final score |
| 1- Bother                | 0.27-0.84       | 0.83           |
| 2 - Frustration          | 0.28-0.85       | 0.85           |
| 3 - Difficulty showing affection | 0.25-0.67       | 0.69           |
| 4- Daily activities      | 0.29-0.75       | 0.77           |
| 5 - Worry about what other people think | 0.17-0.84       | 0.81           |
| 6 - Fear of criticism    | 0.17-0.84       | 0.82           |
| 7 - Embarrassment or inhibition | 0.35-0.85       | 0.83           |
| 8 - Type of clothing     | 0.25-0.68       | 0.72           |
| 9 - Social and leisure activities | 0.30-0.75       | 0.81           |
| 10- Emotional well-being | 0.21-0.75       | 0.83           |
| 11- Physical health as a whole | 0.24-0.71       | 0.70           |
| 12 - Care with personal appearance | 0.24-0.59       | 0.66           |
| 13 - Sun protection care | 0.12-0.35       | 0.41           |
| 14- Making new friends   | 0.12-0.67       | 0.75           |
| 15- Disease progression  | 0.24-0.59       | 0.62           |
DISCUSSION

The development and validation of dermatology-specific QoL questionnaires is recent. For the evaluation of a specific dermatosis, there is a tendency to combine two questionnaires: one generic questionnaire and another disease-specific dermatologic questionnaire, comparing both scores. Disease-specific instruments are already available for several chronic dermatoses, such as atopic dermatitis, acne and melasma.

The absence of a vitiligo-specific questionnaire for the assessment of QoL led to the use of the general dermatology questionnaires, such as DLQI and Skindex-16. However, they do not seem to be sensitive enough for the assessment of an asymptomatic disease such as vitiligo. For conditions like acne and psoriasis, it has been shown that specific questionnaires better reflect QoL. In addition, they make it possible to correlate clinical and demographic aspects of a specific population with QoL.

CONCLUSION

There are little data on the quality of life of patients with vitiligo in Brazil. Most studies have been conducted in children, by using the Children's...
Dermatology Life Quality Index. Studies conducted with adults generally use the DLQI and the SF-36 (Medical Outcomes Study 36-item Short-Form Health Survey). Moving forward, the impact of vitiligo on the quality of life of Brazilian patients can be assessed using a disease-specific questionnaire, which will contribute to a more complete and reliable evaluation of these patients.

REFERENCE

1. Akilhan A, Esteban LM, Daly M, Patricio-Reis V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, pathophysiology, staging, and work-up. J Am Acad Dermatol. 2011;65:473-91.
2. Barona MI, Arruñategui A, Falabella R, Azuela A. An epidemiological case-control study in a population with vitiligo. J Am Acad Dermatol. 1995;125:201-5.
3. Tani RL, Nascimento LM, Moraes CT. Vitiligo–part I. An Bras Dermatol. 2015;90:461-70.
4. Scotti K, Shivade U. Vitiligo: comparison of clinic-epidemiological features. Indian J Dermatol Venereol Leprol. 2007;73:148-90.
5. Liu J, Li M, Yang S, Gu JP, Hong H, Cai WH, et al. Clinical profiles of vitiligo in China: an analysis of 5742 patients. Chin Med J. 2005;30:37-31.
6. Nunes DH, Souza LM. Vitiligo epidemiological profile and the association with thyroid disease. An Bras Dermatol. 2011;86:241-9.
7. Natri DM, Alegre FP, Mendonça RO. Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. Ann J Hum Genet. 1994;55:981-90.
8. Rejal SB, Gade RM, Noseman L, Fadlon R, Goldblatt M. Frequency of autoimmune diseases in those suffering from vitiligo in comparison with normal population. Pain. 2008;4:147-50.
9. Ingordo V1, Cazzaniga S, Raone B, Digiuseppe MD, Musumeci ML, Fai D, et al. Chronic cutaneous autoimmune and autoimmune comorbidities in vitiligo patients: A Multicentre Italian Study. Dermatol. 2014;231:249-50.
10. Takigawa K, Pincro M. Clinical practice: vitiligo. N Engl J Med. 1994;330:149-50.
11. Laude MC, Demid M, Marsano MS, Singh M, Goni MY, Neta AP, et al. Role of oxidative stress and autoimmune in onset and progression of vitiligo, Exp Dermatol. 2014;5:303-3.
12. Wachtler PF, Matsuda PU, Nascimento DC, Tavares CM, Cito NA. Quality of life profile and correlated factors in chronic leg ulcers adaptation in the midwest of Sao Paulo State, Brazil. An Bras Dermatol. 2015;80:73-81.
13. Kamatomi C, Sato S, Hashim RK, Sadek E, Tomlinson J. Acute-specific quality of life questionnaire (Acute-QLQ), translation, cultural adaptation and validation in Brazilian Portuguese language. An Bras Dermatol. 2015;80:83-89.
14. Shrivastava Z, Shiverick KB. Association between vitiligo extent and distribution and quality of life impairment. JAAD Dermatol. 2013;149:156-64.
15. Torquato Milone DS, Estevam-Esperidião V, Guerra F. Quality of life in vitiligo patients. Dermatol Ther. 2012;25:329-37.
16. Flaherty LG, Rees JS, Kissane JM. Psychological well-being of children with vitiligo. J Pediatr. 1993;10:394-14.
17. Lilly E, Lu F, Barosso NL, Worthington ID, Heay J, Doherty D, et al. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL) – A Multicentre Italian Study. Dermatol. 2013;65:473-91.
18. Both W, Esau-Bat ML, Bassrich H, Näppien C. Critical review of general and dermatology-specific health-related quality of life instruments. J Invest Dermatol. 2007;127:2729-36.
19. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:219-36.
20. Da Costa, Mombello PM, Espinagas NA, Boza JD. The suitability of quality-of-life questionnaires for patient research: a systematic literature review. Arch Dermatol. 2006;138:207-17.

Vitiligo is a chronic disease and, although it is asymptomatic, it highly compromises patients’ quality of life (QoL). The translation, cross-cultural adaptation and validation of the VitiQoL-PB will not only assist in treatment evaluation and in the comparison of results of studies conducted in different regions of Brazil, but also allow the correlation with international data.

MAKING ADDRESS:
Juliana Catucci Boza
Rua Ramiro Barcelos, 2350 - Santa Cecília
90035-903 - Porto Alegre - RS
Brazil
E-mail: juliana_boza@yahoo.com.br

How to cite this article: Boza JC, Kundu RV, Fabbri A, Horn R, Giogno N, Cestari TF. Translation, cross-cultural adaptation and validation of the vitiligo-specific health-related quality of life instrument (VitiQoL) into Brazilian Portuguese. An Bras Dermatol. 2015;90(3):358-62.